Table 1.
Demographic and tumor characteristics by diagnostic delay (median diagnostic evaluation, biopsy, and total delay days) among 730 Black and White women who underwent breast cancer screening prior to a breast cancer diagnosis at an Emory University Breast Imaging Center (2010–2014).
| Diagnostic Evaluation Delay | Biopsy Delay | Total Delay | |
|---|---|---|---|
| Demographic Characteristics | Median (IQR) | Median (IQR) | Median (IQR) |
| Total Patient Population | 22 (13, 38) | 7 (3, 15) | 33 (20, 59) |
| Race | |||
| White | 17 (9, 32) | 6 (2, 11) | 26 (15, 49) |
| Black | 27 (18, 42) | 9.5 (5, 19) | 42 (26, 67) |
| Age Category | |||
| <55 | 21 (15, 41) | 7 (3, 13) | 34 (23, 56) |
| 55–64 | 21 (14, 39) | 6 (2, 15) | 30 (19, 56) |
| 65–74 | 24 (13, 40.5) | 7 (3, 15) | 37 (20, 63) |
| >=75 | 21 (12, 37) | 8 (4, 15) | 33 (20, 59) |
| Socioeconomic Status | |||
| 0% – <10% poverty | 20 (13, 31) | 6 (2, 13) | 28 (18, 51) |
| 10% – <20% poverty | 22 (13, 38) | 7 (3, 15) | 34 (19, 59) |
| 20% – 100% poverty | 27 (14, 43) | 10 (4, 18) | 42 (24, 69) |
| Insurance Status | |||
| Uninsured | 28.5 (24, 49) | 13.5 (9, 27) | 44.5 (33, 62) |
| Private | 22 (13, 39) | 7 (2, 14) | 32 (19, 58) |
| Medicaid | 29 (24, 47) | 11 (6, 17) | 39 (29, 84) |
| Medicare | 21 (12, 36) | 8 (3, 16) | 33 (19, 16) |
| Military | 28 (20, 48) | 6 (3, 21) | 43 (26, 54) |
| Unknown | 13 (10, 37.5) | 6.5 (3.5, 12.5) | 21 (14, 50) |
| Geographical Distance to Screening | |||
| Facilities | |||
| Range 1 (0–5.8 miles) | 21 (12, 40) | 7 (2, 16) | 33 (19, 16) |
| Range 2 (5.8–10.8) | 25 (16, 37) | 8 (5, 15) | 37 (25, 60) |
| Range 3(10.8–18.95) | 26 (13, 35.5) | 7 (3, 17) | 35 (20, 57.5) |
| Range 4(18.95–2180.5) | 18 (8, 42) | 6 (3, 13) | 26 (15, 58) |
| Marital Status | |||
| Single | 24 (14, 37) | 9 (4, 21) | 40.5 (21, 63) |
| Married (common law and unmarried domestic) | 21 (13, 36) | 7 (3, 16) | 31 (19.58) |
| Other (divorced, widowed, separated | 25 (13, 42) | 7 (3, 16) | 35.5 (20, 60) |
| Unknown | 15 (9, 28.5) | 6.5 (1, 9) | 23 (17, 38.5) |
| Tumor Characteristics | |||
| Stage | |||
| 0 | 25 (14, 37) | 10 (6, 20) | 37 (22, 61) |
| I | 20 (12, 32.5) | 7 (3, 14) | 29 (17, 49.5) |
| II | 26 (13, 68) | 6 (2, 13) | 39 (21, 109) |
| III | 21 (14, 62) | 6 (1, 10) | 29.5 (20, 87) |
| IV | 52 (19, 203) | 6 (0, 11) | 90 (19, 273) |
| Unknown | 63.5 (47, 179.5) | 9 (2.5, 16.5) | 80 (56, 189.5) |
| Grade | |||
| I | 21 (13, 39) | 7 (3, 17) | 34.5 (19, 56) |
| II | 22 (13, 36) | 7 (3, 15) | 33 (20, 58) |
| III | 22 (13, 42) | 7 (2, 14) | 33.5 (20, 62) |
| Other/unknown | 25 (13, 45) | 6 (2, 18) | 36 (18, 61) |
| Lymph Node Involvement | |||
| 1–3 positive | 25 (13, 52) | 5 (2, 9) | 32 (17, 87) |
| 3+ | 20 (15, 47) | 7 (3, 11) | 28 (22, 58) |
| Negative | 22 (13, 37) | 7 (3, 14) | 32 (20, 58) |
| Unknown/no nodes examined | 22 (12, 37) | 8 (5, 19) | 37 (20, 62) |
| Tumor Size | |||
| ≤1 cm | 22 (13, 34) | 8 (4, 15) | 34 (20, 54) |
| 1–5 cm | 21 (13, 40) | 6 (2,13) | 31 (19, 58) |
| ≥5 cm | 27 (13, 45) | 10.5 (6, 20) | 43 (21, 72) |
| Subtype | |||
| Luminal A | 21 (12, 37) | 6.5 (3, 13) | 31 (18, 53.5) |
| Luminal B | 22.5 (16, 53) | 6.5 (2, 11) | 34.5 (22, 89) |
| HER2-overexpressing | 21 (18, 71) | 7 (2, 14) | 31 (20, 93) |
| TNBC | 28 (17, 54) | 7 (1, 14) | 43 (21, 68) |
| Unknown | 23 (13, 36) | 10 (6, 20) | 36 (22, 61) |
| ER Status | |||
| ER+ | 21 (13, 38) | 6.5 (3, 13) | 31 (18, 56) |
| ER− | 28 (17. 56) | 7 (1, 14) | 42 (21, 69) |